Farmapram (alprazolam) is an anxiolytic medicine (tranquilizer) from the group of benzodiazepines of medium duration of action, also has sedative-hypnotic effect. Farmapram enhances inhibitory effects of endogenous GABA (mediator of pre- and postsynaptic inhibition in the CNS).
Nervous system disorders: at the beginning of treatment (especially in elderly patients) – drowsiness, fatigue, dizziness, decreased ability to concentrate, ataxia, disorientation, slowed mental and motor reactions; rarely – headache, euphoria, depression, tremor, memory loss, movement coordination disorders, depressed mood, confusion, dystonic extrapyramidal reactions (uncontrollable movements, including eye movements), weakness. weakness, myasthenia gravis, dysarthria; extremely rare – paradoxical reactions (aggressive outbursts, confusion, psychomotor agitation, fear, suicidal tendencies, muscle spasm, hallucinations, agitation, irritability, anxiety, insomnia). Blood organs: leukopenia, neutropenia, agranulocytosis (chills, hyperthermia, sore throat, excessive fatigue or weakness), anemia, thrombocytopenia.
Digestive system: dry mouth or salivation, heartburn, nausea, vomiting, decreased appetite, constipation or diarrhea; liver dysfunction, increased liver transaminases and alkaline phosphatase activity, jaundice.
Urogenital system: urinary incontinence, urinary retention, renal dysfunction, decreased or increased libido, dysmenorrhea.
Allergic reactions: skin rash, itching.
Effect on the fetus: teratogenicity (especially I trimester), CNS depression, respiratory disorders and suppression of the sucking reflex in newborns whose mothers used the drug.
Other: addiction, drug dependence, decreased BP, rarely – visual impairment (diplopia), weight loss, tachycardia. Withdrawal syndrome (irritability, nervousness, sleep disturbances, dysphoria, spasm of smooth muscles of internal organs and skeletal muscles, depersonalization, increased sweating, depression, nausea, vomiting, tremor, perception disorders, including hyperacusis, paresthesia, photophobia; tachycardia, seizures, rarely – acute psychosis) occur after a sharp dose reduction or discontinuation of use.
Caution. Hepatic insufficiency, CPN, cerebral and spinal ataxia, drug addiction in anamnesis, psychoactive drugs abuse tendency, hyperkinesia, organic brain disease, psychosis (paradoxical reactions are possible), hypoproteinemia, nocturnal apnea (established or suspected), old age.
Fetal Action Category. D
Symptoms (500-600 mg): drowsiness, confusion, decreased reflexes, nystagmus, tremor, bradycardia, shortness of breath or difficulty in breathing, decreased BP, coma.
Treatment: gastric lavage, intake of activated charcoal. Symptomatic therapy (maintenance of breathing and BP), injection of flumazenil (in hospital conditions). Hemodialysis is ineffective.